Trials / Unknown
UnknownNCT03634059
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po |
Timeline
- Start date
- 2018-08-15
- Primary completion
- 2019-08-15
- Completion
- 2020-08-15
- First posted
- 2018-08-16
- Last updated
- 2018-08-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03634059. Inclusion in this directory is not an endorsement.